Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6447-6455

  Tradtrantip, Lukmanee ^a   Sonawane, N D ^a   Wan, Namkung ^a   Verkman, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,9 DIMETHYL 11 PHENYL 6 (5 METHYLFURAN 2 YL) 5,6 DIHYDRO PYRIMIDO[4',5' 3,4]PYRROLO[1,2 A]QUINOXALINE 8,10 (7H,9H)DIONE; PROTEIN INHIBITOR; PYRIMIDO PYRROLO QUINOXALINEDIONE; QUINOXALINE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; EPITHELIUM CELL; HUMAN; HUMAN CELL; IC 50; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PATCH CLAMP; PH MEASUREMENT; PROTEIN EXPRESSION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIALS; MICE; POLYCYSTIC KIDNEY DISEASES; QUINOXALINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350070383     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9009873     Document Type: Article

References (30)

1. Sheppard, D. N.; Welsh, M. J. Structure and function of the CFTR chloride channel. Physiol. Rev. 1999, 79, S23-45.
2. Gadsby, D. C.; Vergani, P.; Csanády, L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006, 440, 477-483.
3. Thiagarajah, J.; Broadbent,T.;Hsieh, E.;Verkman,A. S. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 2004, 126, 511-519.
4. Sonawane, N.; Zhao, D.; Zegarra-Moran, O.; Galietta, L. J. V.; Verkman, A. S. Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology 2007, 132, 1234-1244.
5. Kunzelmann, K.; Mall, M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol. Rev. 2002, 82, 245-289.
6. Hanaoka, K.; Guggino, W. B. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 2000, 11, 1179-1187.
7. Brill, S. R.; Ross, K. E.; Davidow, C. J.; Ye, M.; Grantham, J. J.; Caplan, M. J. Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10206-10211.
8. Torres, V. E.; Harris, P. C. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat. Clin. Pract. Nephrol. 2006, 2, 40-55.
9. O'Sullivan, D. A.; Torres, V. E.; Gabow, P. A.; Thibodeau, S. N.; King, B. F.; Bergstralh, E. J. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 1998, 32, 976-983.
10. Xu, N.; Glockner, J. F.; Rossetti, S.; Babovich-Vuksanovic, D.; Harris, P. C.; Torres, V. E. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J. Nephrol. 2006, 19, 529-534. (Pubitemid 44823212)
11. Cotton, C. U.; Avner, E. D. PKD and CF: an interesting family provides insight into the molecular pathophysiology of polycystic kidney disease. Am. J. Kidney Dis. 1998, 32, 1081-1083.
12. Davidow, C. J.; Maser, R. L.; Rome, L. A.; Calvet, J. P.; Grantham, J. J. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int. 1996, 50, 208-218.
13. - secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int. 2004, 66, 1926-1938.
14. Routaboul, C.; Norez, C.; Melin, P.; Molina, M. C.; Boucherle, B.; Bossard, F.; Noel, S.; Robert, R.; Gauthier, C.; Becq, F.; Decout, J. L. Discovery of α-aminoazaheterocycle-methylglyoxal adducts as a new class of high-affinity inhibitors of cystic fibrosis transmembrane conductance regulator chloride channels. J. Pharmacol. Exp. Ther. 2007, 322, 1023-1035.
15. Sonawane, N. D.; Zegarra-Moran, O.; Namkung, W.; Galietta, L. J. V.; Verkman, A. S. α-Aminoazaheterocyclic-methylglyoxyl adducts do not inhibit cystic fibrosis transmembrane conductance chloride channel activity. J. Pharm. Exp. Ther. 2008, 325, 529-535.
16. Ma, T.; Thiagarajah, J. R.; Yang, H.; Sonawane, N. D.; Folli, C.; Galietta, L. J.; Verkman, A. S. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera-toxin induced intestinal fluid secretion. J. Clin. Invest. 2002, 110, 1651-1658.
17. Taddei, A.; Folli, C.; Zegarra-Moran, O.; Fanen, P.; Verkman, A. S.; Galietta, L. J. Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett. 2004, 558, 52-56.
18. inh-172 based on arginine 347 mutagenesis. Biochem. J. 2008, 413, 135-142.
19. Sonawane, N. D.; Muanprasat, C.; Nagatani, R.; Song, Y.; Verkman, A. S. In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents. J. Pharm. Sci. 2005, 94, 134-143.
20. Muanprasat, C.; Sonawane, N. D.; Salinas, D.; Taddei, A.; Galietta, L. J. V.; Verkman, A. S. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis and in vivo efficacy. J. Gen. Physiol. 2004, 124, 125-137.
21. Sonawane,N.D.;Hu, J.;Muanprasat,C.;Verkman,A. S.Luminally-active, nonabsorbableCFTRinhibitors as potential therapy to reduce intestinal fluid losses in cholera. FASEB J. 2006, 20, 130-132.
22. Sonawane,N.;Zhao,D.;Zegarra-Mora,O;Galietta,L. J.;Verkman, A. S. Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycol-malonic acid hydrazides. Chem. Biol. 2008, 15, 718-728.
23. Yang, B.; Sonawane, N. D.; Zhao, D.; Somlo, S.; Verkman, A. S. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol. 2008, 19, 1300-1310.
24. Sonawane, N.; Verkman, A. S. Thiazolidinone CFTR inhibitors with improved water solubility identified by structure - activity analysis. Bioorg. Med. Chem. 2008, 16, 8187-8195.
25. Verkman, A. S.; Galietta, L. J. Chloride channels as drug targets. Nat. Rev. Drug Discovery 2009, 8, 153-171.
26. - co-transporter-dependent cystic dilation. J. Am. Soc. Nephrol. 2006, 17, 3424-3437.
27. Azas, N.; Rathelot, P.; Djekou, S.; Delmas, F.; Gellis, A.; Di Giorgio, C.; Vanelle, P.; Timon-David, P. Antiparasitic activity of highly conjugated pyrimidine-2,4-dione derivatives. Farmaco 2003, 58, 1263-1270. (Pubitemid 37433850)
28. Tsupak, E. B.; Shevchenko, M. A.; Pozharskii, A. F.; Tkachenko, Y. N. Pyrollopyrimidines. 5. Interaction of 6-amino-1,3-dimethylpyrrolo[3,4-d]- pyrimidin-2,4(1H,3H)-diones with 1,3-diketones. Khim. Geterotsikl. Soedin. 2003, 7, 1096-1102.
29. Tsupak, E. B.; Shevchenko, M. A. [3,4]-annulated pyrroles 1. Polynuclear heterocyclic systems based on pyrrolo[3,4-d]pyrimidine- 2,4-dione. Russ. Chem. Bull. 2006, 55, 2265-2270.
30. Oels, R.; Storer, R.; Young, D. W. Reinvestigation of synthesis of 3-dimethylallyl-4-hydroxy-2-quinolones - novel route to tetracyclic heteroaromatic-compounds. J. Chem. Soc., Perkin Trans. 1977, 23, 2546-2551.